{
  "abstract": "Background\n\nAnthracycline-containing intensive chemotherapy remains a standard frontline approach for medically fit patients with acute myeloid leukemia (AML). We retrospectively evaluated an exploratory anthracycline-sparing regimen combining fludarabine, cytarabine, and venetoclax (FLA-VEN), with midostaurin added in FLT3-mutated cases, in selected patients with intermediate- or adverse-risk AML.Methods\n\nThis retrospective single-center study included 24 consecutive adults with newly diagnosed intermediate- or adverse-risk AML treated between March 2024 and March 2026. Patients with favorable-risk AML were excluded. The primary endpoints were complete remission (CR) and safety. Secondary endpoints included hematologic recovery, allogeneic hematopoietic stem cell transplantation (allo-HSCT) rate, relapse incidence, transplant-related mortality (TRM), and overall survival (OS).Results\n\nThe median age was 49 years (range, 22-64), and 16.7% of patients were aged ≥60 years. FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations were present in 8 patients (33.3%). Following one induction cycle, 21 of 24 patients (87.5%) achieved CR. Among FLT3-ITD-mutated patients, 7 of 8 (87.5%) achieved CR, and FLT3-ITD became undetectable by the available polymerase chain reaction (PCR) fragment assay in all seven responders before transplantation. The 60-day mortality rate was 0/24 (0%). Median neutrophil and platelet recovery times were 17 and 21 days, respectively. Twenty-one patients (87.5%) underwent allo-HSCT in first remission. With a database cutoff of 30 August 2026, Kaplan-Meier estimated OS was 83.3% (95% CI, 61.5-93.4%) at 12 months. The longer-term 24-month OS estimate was 54.4% (95% CI, 25.5-76.3%); however, this estimate was imprecise because only five patients remained at risk at 24 months. Median OS was not reached.Conclusions\n\nIn this small exploratory cohort, anthracycline-free and G-CSF-free FLA-VEN, with or without midostaurin, was associated with high remission rates, no early mortality, and frequent bridging to allo-HSCT. These findings support prospective controlled evaluation of this anthracycline-sparing strategy.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Hematology, Faculty of Medicine, Dokuz Eylül University, 35340 İzmir, Türkiye.",
    "Department of Hematology, University of Health Sciences Türkiye, İzmir Tepecik Training and Research Hospital, 35020 İzmir, Türkiye."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Sinem Namdaroglu"
    },
    {
      "affs": [
        0
      ],
      "name": "Merve Kakcı"
    },
    {
      "affs": [
        0
      ],
      "name": "Berrak Şenol"
    },
    {
      "affs": [
        0
      ],
      "name": "Osman Can Öztürk"
    },
    {
      "affs": [
        0
      ],
      "name": "Ömer Şeker"
    },
    {
      "affs": [
        1
      ],
      "name": "Mehmet Can Uğur"
    },
    {
      "affs": [
        1
      ],
      "name": "Nanişe Gizem Fener"
    },
    {
      "affs": [
        0
      ],
      "name": "Semih Başcı",
      "orcid": "0000-0003-4304-9245"
    },
    {
      "affs": [
        0
      ],
      "name": "Hikmetullah Batgi"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/2vtabv187vwr6.bib",
  "cited_by": 0,
  "doi": "10.3390/cancers18193132",
  "fulltext_url": "https://europepmc.org/articles/PMC13664420",
  "id": "2vtabv187vwr6",
  "issns": [
    "2072-6694"
  ],
  "landing_url": "https://europepmc.org/article/MED/42882827",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2720|Acute Myeloid Leukemia Research"
    ]
  ],
  "openalex": "W7214585273",
  "pdf_url": "https://europepmc.org/articles/PMC13664420?pdf=render",
  "pmcid": "PMC13664420",
  "pmid": "42882827",
  "published": "2026-09-27",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/2vtabv187vwr6.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:16Z",
      "native_id": "MED:42882827",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42882827"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2072-6694",
      "subfield": "oncology"
    }
  ],
  "title": "Anthracycline-Free FLA-VEN with or Without Midostaurin in Newly Diagnosed Intermediate- and Adverse-Risk AML: A Single-Center Retrospective Study.",
  "title_text": "Anthracycline-Free FLA-VEN with or Without Midostaurin in Newly Diagnosed Intermediate- and Adverse-Risk AML: A Single-Center Retrospective Study.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:19:16Z",
  "url": "https://research.draconitic.com/paper/2vtabv187vwr6",
  "venue": "Cancers",
  "versions": []
}